GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (FRA:7EY) » Definitions » Debt-to-Asset

Kiora Pharmaceuticals (FRA:7EY) Debt-to-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kiora Pharmaceuticals Debt-to-Asset?

Kiora Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.04 Mil. Kiora Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.04 Mil. Kiora Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €37.92 Mil. Kiora Pharmaceuticals's debt to asset for the quarter that ended in Jun. 2024 was 0.00.


Kiora Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Kiora Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Debt-to-Asset Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.04 0.01 0.01 0.01

Kiora Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 - -

Competitive Comparison of Kiora Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Kiora Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Debt-to-Asset falls into.



Kiora Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kiora Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Kiora Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiora Pharmaceuticals  (FRA:7EY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Kiora Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals Business Description

Traded in Other Exchanges
Address
332 Encinitas Boulevard, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals Headlines

No Headlines